Analysis of a successful immune response against hepatitis C virus.

To investigate the type of immunity responsible for resolution of hepatitis C virus (HCV) infection, we monitored antibody and intrahepatic cytotoxic T lymphocyte (CTL) responses during acute (<20 weeks) infection in chimpanzees. Two animals who terminated infection made strong CTL but poor antibody responses. In both resolvers, CTL targeted at least six viral regions. In contrast, animals developing chronic hepatitis generated weaker acute CTL responses. Extensive analysis of the fine specificity of the CTL in one resolver revealed nine peptide epitopes and restriction by all six MHC class I allotypes. Every specificity shown during acute hepatitis persisted in normal liver tissue more than 1 yr after resolution. These results suggest that CD8+CTL are better correlated with protection against HCV infection than antibodies.

[1]  B. Walker,et al.  Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. , 1992, Journal of immunology.

[2]  L. V. Doorn.  Molecular biology of the hepatitis C virus , 1994 .

[3]  H. Popper,et al.  Non‐A, Non‐B Hepatitis‐Related Hepatocellular Carcinoma in a Chimpanzee , 1988, Journal of medical primatology.

[4]  M. Houghton,et al.  Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. , 1993, Journal of immunology.

[5]  J. Drazen,et al.  Sorting out the cytokines of asthma , 1996, The Journal of experimental medicine.

[6]  P. Parham,et al.  Structural heterogeneity in HLA-B70, a high-frequency antigen of black populations. , 1993, Tissue antigens.

[7]  J. Ray,et al.  Styles of dominance and their endocrine correlates among wild olive baboons (Papio anubis) , 1989, American journal of primatology.

[8]  N. Hayashi,et al.  Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus , 1998, Hepatology.

[9]  M. Davis,et al.  Expression of T cell antigen receptor heterodimers in a lipid-linked form. , 1990, Science.

[10]  S. Frøland,et al.  Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. , 1994, The New England journal of medicine.

[11]  H. Thomas,et al.  Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. , 1994, Gastroenterology.

[12]  M. Houghton,et al.  Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses , 1993, Journal of virology.

[13]  P. Parham,et al.  Comparison of Class I MHC Alleles in Humans and Apes , 1990, Immunological reviews.

[14]  R. Bontrop,et al.  Evolution of Major Histocompatibility Complex Polymorphisms and T‐Cell Receptor Diversity in Primates , 1995, Immunological reviews.

[15]  R. Lanford,et al.  Analysis of Hepatitis C Virus-Inoculated Chimpanzees Reveals Unexpected Clinical Profiles , 1998, Journal of Virology.

[16]  E. Adams,et al.  A major histocompatibility complex class I allele shared by two species of chimpanzee , 1998, Immunogenetics.

[17]  P. Parham,et al.  Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CD8+ cytotoxic T cells from two chronically infected chimpanzees , 1996, The Journal of experimental medicine.

[18]  E. Tanaka,et al.  Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C , 1997, Journal of gastroenterology and hepatology.

[19]  M. Massari,et al.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. , 1996, The Journal of clinical investigation.

[20]  M. Houghton,et al.  Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease , 1991, Hepatology.

[21]  Q. Choo,et al.  Use of recombinant HCV antigen in the serodiagnosis of hepatitis C virus infection: Significant improvement in HCV antibody detection as compared with the first generation HCV C100‐3 ELISA and the synthetic peptide EIA tests , 1993 .

[22]  F. Chisari,et al.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. , 1995, The Journal of clinical investigation.

[23]  L. Corey,et al.  Detection of hepatitis C virus RNA: comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR , 1993, Journal of clinical microbiology.

[24]  G. Kotwal,et al.  Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children. , 1997, The Pediatric infectious disease journal.

[25]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[26]  Jules L. Dienstag,et al.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis , 1989 .

[27]  A. Hughes,et al.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Walker,et al.  Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. , 1997, The Journal of infectious diseases.

[29]  Q. Choo,et al.  Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. Chisari,et al.  Induction in vitro of a primary human antiviral cytotoxic T cell response , 1995, European journal of immunology.

[31]  S. Mishiro,et al.  Full-length nucleotide sequence of a Japanese hepatitis C virus isolate (HC-J1) with high homology to USA isolates. , 1992, Nucleic acids research.

[32]  M. Houghton,et al.  Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C , 1993, The Journal of experimental medicine.

[33]  P. Parham,et al.  The presentation of a hepatitis C viral peptide by distinct major histocompatibility complex class I allotypes from two chimpanzee species , 1996, The Journal of experimental medicine.

[34]  R. Demars,et al.  Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. , 1989, Journal of immunology.

[35]  Miriam J. Alter.  Epidemiology of hepatitis C. , 1996 .

[36]  R. Chapman,et al.  Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up , 1997, Clinical and experimental immunology.

[37]  T. Santantonio,et al.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection , 1995, The Lancet.

[38]  P. Schirmacher,et al.  Detection of hepatitis C virus in paraffin‐embedded liver biopsies of patients negative for viral RNA in serum , 1999, Hepatology.

[39]  C. Rice,et al.  The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. , 1997, Journal of immunology.

[40]  D. Watkins.  The evolution of major histocompatibility class I genes in primates. , 1995, Critical reviews in immunology.

[41]  P. Barr,et al.  Genetic organization and diversity of the hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Chisari,et al.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. , 1996, The Journal of clinical investigation.